Abstract
Background
Primary mast cell activation syndromes (MCAS) are a group of disorders presenting with symptoms of mast cell mediator release.
Objectives
To assess the effectiveness and safety of orally-administered H1-antihistamines in the treatment of primary MCAS compared with placebo and other pharmacologic treatments.